922719-76-4

Usage

Uses

Used in Organic Synthesis:
(2,5-difluoro-4-methoxyphenyl)methanol is utilized as a building block in the production of various pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable component in the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2,5-difluoro-4-methoxyphenyl)methanol is used as a key intermediate for the synthesis of novel drugs. Its presence in the molecular structure can contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, (2,5-difluoro-4-methoxyphenyl)methanol serves as an essential intermediate for the development of new pesticides and other agrochemical products. Its incorporation into these compounds can enhance their performance and selectivity in agricultural applications.
Used in Reagent Preparation:
(2,5-difluoro-4-methoxyphenyl)methanol can also be used as a reagent in the preparation of other organic compounds. Its versatility allows it to be employed in various chemical reactions, contributing to the synthesis of a diverse array of organic molecules.
Used in Synthesis of Novel Materials and Nanocomposites:
Furthermore, (2,5-difluoro-4-methoxyphenyl)methanol may have potential applications as an intermediate for the synthesis of novel materials and nanocomposites. Its unique properties could be harnessed to develop new materials with specific characteristics for use in various industries.

Upstream product

• 879093-08-0 2,5-difluoro-4-methoxybenzaldehyde 
• 1060739-01-6 2,5-difluoro-4-methoxybenzoic acid 

Downstream Products

• 879093-08-0 2,5-difluoro-4-methoxybenzaldehyde 
• 873373-81-0 1-(bromomethyl)-2,5-difluoro-4-methoxybenzene 

Relevant academic research and scientific papers

BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

The invention relates toa pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the trea

METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES

The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for